Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes

Table 1 Phase I studies on intraperitoneal chemotherapy using taxanes for the treatment of gastric cancer with peritoneal carcinomatosis

Ref.	n	Intraperitoneally administered taxanes	Initial dose(mg/m2)	MTD(mg/m2)	RD(mg/m2)	DLT
Kodera et al[42]	4	PTX	60	-	-	-
Fushida et al[26]	24	DOC	25	60	45	Abdominal pain and
						diarrhea
Ishigami et al[45]	9	PTX	20	30	20	Febrile neutropenia and diarrhea
Fujiwara et al[43]	12	DOC	40	-	60	-
Kurita et al[44]	18	PTX	40	90	80	Leukocytopenia
Fushida et al[16]	12	DOC	35	50	45	Febrile neutropenia and diarrhea

MTD: Maximum tolerated dose; RD: Recommended dose; DLT: Dose-limiting toxicities; PTX: Paclitaxel; DOC: Docetaxel.

Table 2 Phase II studies on intraperitoneal chemotherapy using taxanes for the treatment of gastric cancer with peritoneal carcinomatosis

Ref.	n	Method	Intraperitoneally administered agents	MST (mo)	1-yr OS (%)	2-yr OS (%)	5-yr OS (%)
Yonemura et al[38]	61	NIPS	DOC (40 mg) + CBDCA (150 mg)	14.4	67
Ishigami et al[14]	40	SPIC	PTX (20 mg/m2)	22.6	78
Fujiwara et al[17]	18	NIPS	DOC (40-60 mg/m2)	24.6	76	54
Imano et al[39]	35	NIPS	PTX (80 mg/m2)	21.3	69	46	14
Yamaguchi et al[15]	35	SPIC	PTX (20 mg/m2)	17.6	77	45
Fushida et al[16]	27	SPIC	DOC (35-50 mg/m2)	16.2	70	33

MST: Median survival time; OS: Overall survival; DOC: Docetaxel; CBDCA: Carboplatin; PTX: Paclitaxel; NIPS: Neoadjuvant intraperitoneal and systemic chemotherapy; SPIC: Sequential perioperative intraperitoneal chemotherapy.